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Background: Aberrant methylation at imprinted differentially methylated regions (DMRs) in human 11p15.5 has
been reported in many tumors including hepatoblastoma. However, the methylation status of imprinted DMRs in
imprinted loci scattered through the human genome has not been analyzed yet in any tumors.
Methods: The methylation statuses of 33 imprinted DMRs were analyzed in 12 hepatoblastomas and adjacent normal
liver tissue by MALDI-TOF MS and pyrosequencing. Uniparental disomy (UPD) and copy number abnormalities were
investigated with DNA polymorphisms.
Results: Among 33 DMRs analyzed, 18 showed aberrant methylation in at least 1 tumor. There was large deviation
in the incidence of aberrant methylation among the DMRs. KvDMR1 and IGF2-DMR0 were the most frequently
hypomethylated DMRs. INPP5Fv2-DMR and RB1-DMR were hypermethylated with high frequencies. Hypomethylation
was observed at certain DMRs not only in tumors but also in a small number of adjacent histologically normal
liver tissue, whereas hypermethylation was observed only in tumor samples. The methylation levels of long
interspersed nuclear element-1 (LINE-1) did not show large differences between tumor tissue and normal liver
controls. Chromosomal abnormalities were also found in some tumors. 11p15.5 and 20q13.3 loci showed the
frequent occurrence of both genetic and epigenetic alterations.
Conclusions: Our analyses revealed tumor-specific aberrant hypermethylation at some imprinted DMRs in 12
hepatoblastomas with additional suggestion for the possibility of hypomethylation prior to tumor development.
Some loci showed both genetic and epigenetic alterations with high frequencies. These findings will aid in
understanding the development of hepatoblastoma.
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Hepatoblastoma is the most common primary liver tumor
in children, accounting for just over 1% of pediatric cancers
and 79% of liver cancers in children under the age of 15 [1].
Most of these tumors are purely derived from epithelium
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reproduction in any medium, provided the orknown as fetal and embryonal types. The fetal type consists
of smaller than normal hepatocytes that are arranged in
irregular laminae, recapitulating those of the fetal liver.
The embryonal type is comprised of smaller cells as
compared to the fetal type. It has a more immature
appearance and pattern of growth. Some of the tumors,
referred to as mixed type, are characterized by epithelial
patterns and spindled mesenchymal cells. A much rarer
variant of such mixed type tumor harbors teratoid features,
which contains foci of mature cartilage, intestinal-type
or keratinized epithelium, melanin pigment, or skeletalral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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To date, several genetic and epigenetic features have
been observed in hepatoblastoma (reviewed in [2]). The
most recurrent cytogenetic abnormalities include the
presence of extra copies of chromosomes 2, 8, 20, and
the loss of chromosome 4. Mutations or upregulation
of the genes involved in embryonic development have
been reported. For example, APC, CTNNB1, AXIN1,
and AXIN2 (key factors involved in the Wnt signaling
pathway) are frequently mutated, suggesting that aber-
ration of this pathway occurs as an early event during
tumorigenesis. Mutation of PIK3CA, amplification of
PIK3C2B, and upregulation of hedgehog ligands and
their target genes have also been reported. Epigenetic
silencing by promoter hypermethylation occurs at several
tumor suppressor genes, such as SFRP1, APC, HHIP,
SOCS1, CASP8, and RASSF1A. In addition, several
imprinted genes, including IGF2, DLK1, PEG3, PEG10,
MEG3, and NDN, have been reported to be overexpressed
in hepatoblastoma [2].
Imprinted genes are expressed in a parent-of-origin-
specific manner. They are usually clustered in subchro-
mosomal regions called imprinting domains. The human
genome contains more than 30 imprinting domains (http://
www.geneimprint.com). Imprinting domains have at least
one DMR that are characterized by DNA methylation
on one of the two parental alleles. There are maternally
methylated DMRs and paternally methylated DMRs. In
addition, two classes of imprinted DMRs, gametic and
somatic, have been described. Gametic DMRs acquire
methylation during gametogenesis and the methylation
is maintained from zygote to somatic cells during all
the developmental stages. Most gametic DMRs are known
as imprinting control regions (ICRs) that regulate the
imprinted expression of the genes in the domain. By
contrast, methylations of somatic DMRs are established
during early embryogenesis after fertilization under the
control of nearby ICRs [3]. Somatic DMRs also regulate
the expression of the imprinted genes.
Many imprinted genes regulate cell growth and differen-
tiation, and, thus, disruption of imprinting, mainly due
to aberrant DNA methylation at the responsible DMR,
is implicated in pre- and/or post-natal growth disorders
and in the pathogenesis of cancers [4]. For example,
hypermethylation of H19-DMR, which is the ICR of the
IGF2/H19 imprinting domain at the 11p15.5 locus, is a
cause of Beckwith-Wiedemann syndrome (BWS), the
most common overgrowth syndrome characterized by
occasional development of embryonal tumors, including
hepatoblastoma [5]. The hypermethylation leading to
biallelic expression of IGF2 is seen in a range of tumors,
also including hepatoblastoma [6,7]. The LOH of 11p15.5,
especially the loss of the maternal allele, is found in
approximately 20% of hepatoblastoma cases, and it isreported to be a risk factor for the relapse of this tumor
[7,8]. Furthermore, several imprinted genes are overex-
pressed in hepatoblastoma as mentioned above. Thus,
it is speculated that aberrant DNA methylation at
imprinted DMRs is a key mechanism during malignant
transformation of progenitor cells in a variety of tissues,
including the liver [2,9]. However, the methylation status
of imprinted DMRs scattered through the human genome
has yet to be analyzed comprehensively in hepatoblastoma.
In this study, we performed comprehensive methylation
analyses and polymorphism analyses of 33 imprinted DMRs
in hepatoblastoma. We therefore describe some epigenetic
and genetic characteristics of hepatoblastoma. These




Twelve hepatoblastomas and their paired adjacent normal
liver tissues were analyzed. Eleven sporadic hepatoblas-
toma samples (HB01 - HB11) were obtained from the
Department of Pediatric Surgery, Faculty of Medicine,
Kyushu University, Japan. One hepatoblastoma developed
in a BWS patient (BWS109) was obtained from Toho
University, Omori Medical Centre, Japan. Histochemical
analyses of the tumor tissues indicated that the average of
the tumor cell contents was approximately 70%. Ten of
the patients were treated based on the Japanese Study
Group for Pediatric Liver Tumor-2 (JPLT-2) protocol
(HB08 and HB09 were not). Clinical information of the
hepatoblastoma cases is shown in Table 1. Three livers
(CL7, CL16, CBD1) were used as normal controls. CL7 (a
7-year-old who died from spinal muscular atrophy type
I-C with chronic respiratory insufficiency) and CL16 (a
16-year-old who died after head trauma) were provided by
the non-profit organization, Human & Animal Bridging
Research Organization (Chiba, Japan). CBD1 (a 7-month-
old who had congenital biliary dilatation) was obtained
from the Department of Pediatric Surgery, Faculty of
Medicine, Kyushu University. Written informed consents
were obtained from the parents or the guardians of the
participants, because the participants were children or
dead. This study was approved by the Ethical Committee
for Human Genome and Gene Analyses of the Faculty of
Medicine, Saga University.
DNA isolation and bisulphite conversion
Genomic DNA was extracted from each sample using
the QIAamp DNA Mini Kit (Qiagen, Germany) accord-
ing to the manufacturer’s instructions. One microgram
of genomic DNA was subjected to bisulfite conversion
using the EZ DNA Methylation KitTM (Zymo Research,
CA), and then the converted DNA was eluted in 100 μl
of water.
Table 1 Clinical information of hepatoblastoma cases
Case Sex/agea Histology PRETEXT Preoperative chemotherapyb POSTTEXT Outcome Other information
HB01 F/1y3m Combined fetal and embryonal type III CITA4 III Alive
HB02 F/3y2m Fetal typec III CITA4 III Aive
HB03 F/7y11m Hepatoblastoma (NOS)d III CITA5 III Alive Small for gestational age
HB04 M/1y4m Mixed epithelial and mesenchymal with teratoid featurec IV CITA4 + ITEC2 IV Alive
HB05 M/1y2m Mixed epithelial and mesenchymal with teratoid feature III CITA5 II Alive
HB06 M/10m Mixed epithelial and mesenchymal with teratoid feature III CITA4 III Alive
HB07 M/8m Combined fetal and embryonal type II CITA2 II Alive
HB08 F/28d Combined fetal and embryonal type II Alive
HB09 M/1y6m Combined fetal and embryonal type II Treatment related death Small for gestational age
HB10 F/6y6m Fetal type II CITA2 II Alive
HB11 F/3m Combined fetal and embryonal type IV CITA7 III Treatment related death
BWS109 F/1y0m Hepatoblastoma (NOS)d IV,M(+) CITA7 + ITEC1 IV Alive Beckwith-Wiedemann syndrome,
liver transplantation at 1 year old
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The methylation status of imprinted DMRs was screened
by MALDI-TOF MS analysis with a MassARRAY system
(Sequenom, CA) [10], according to the manufacturer’s
instructions. MALDI-TOF MS analysis produced signal
pattern pairs indicative of non-methylated and methylated
DNA. Epityper software analysis of the signals yielded the
methylation index which ranged from 0 (no methylation)
to 1 (full methylation) of each CpG unit, which contained
one or more CpG sites measured as one unit in the
MALDI-TOF MS analysis. Aberrant methylation of a CpG
unit was defined as when the difference of methylation
indexes between two samples exceeded 0.15, which was
based on the fact that we have previously found that the
differences of H19-DMR hypermethylation or KvDMR1
hypomethylation in BWS patients were at least more
than 0.15 (data not shown). Since analyzed DMRs
included several CpG units, aberrant methylation of a
DMR was defined as when more than 60% of total
number of analyzed CpG units showed aberrant
methylation (with the difference exceeding 0.15). We
used CL7 and CBD1 as normal controls in MALDI-
TOF MS analysis.Pyrosequencing
Pyrosequencing was conducted using QIAGEN PyroMark
Q24 according to the manufacturer’s instruction (Qiagen,
Germany). Some of the primers for DMR analysis were
described by Woodfine et al. [11]. We designed other
primers by using PyroMark Assay Design 2.0 (Qiagen,
Germany). The primers for LINE-1 (GenBank accession
no. X58075) analyses were described by Bollati et al.
[12]. The criterion for MALDI-TOF MS analysis was
also employed to define the aberrant methylation of
each CpG site and an analyzed region. We used three
livers, i.e. CL7, CL16, and CBD1, as normal controls in
pyrosequencing. The control livers were analyzed in
triplicate for LINE-1 and once for DMRs.DNA Polymorphism analysis
LOH, UPD, and copy number abnormalities were investi-
gated with DNA polymorphisms. For quantitative ana-
lyses, tetranucleotide repeat markers near the imprinted
DMRs were amplified and separated by electrophoresis on
an Applied Biosystems 3130 genetic analyzer. Data were
then quantitatively analyzed with GeneMapper software
(Applied Biosystems, CA). The peak height ratios of
two parental alleles were calculated. A single nucleotide
polymorphism (SNP) of KCNQ1DN (rs229897) was also
analyzed.
All primers used in this study are shown in Additional
file 1: Table S1.Statistical analysis
The methylation statuses of the samples were compared
in three pairs: adjacent normal liver tissue (A) and control
livers (C), denoted as AxC; tumors (T) and control livers,
denoted as TxC; tumors and adjacent normal liver
tissue, denoted as TxA. The binomial distribution test
was performed to compare aberrant hypomethylation and
aberrant hypermethylation within each comparison pair
(AxC, TxC, and TxA). The Chi squared test or Fisher’s
exact test was used for comparison between maternally
methylated and paternally methylated DMRs and between
gametic and somatic DMRs in aberrant hypomethylation
and aberrant hypermethylation cases for each comparison
pair. For LINE-1 methylation, a paired t-test was used
to compare tumor and adjacent normal liver tissue, and
an independent t-test (Welch’s t-test) was used for
comparing tumor or adjacent normal liver tissue with
control liver. A p-value less than 0.05 was considered
to be statistically significant. Bonferroni correction was
performed when needed.
Results
Clinical information of hepatoblastoma cases
Clinical information of the 12 hepatoblastoma cases ana-
lyzed in this study are shown in Table 1. Eleven tumors
were sporadic (HB01-HB11), and one was associated
with BWS (BWS109). The ratio of males to females was
5:7. The mean age at diagnosis was 25.7 months, ranging
from 28 days to 7 years and 11 months. In terms of
histological features, 5 cases had combined fetal and
embryonal types, 3 cases had mixed epithelial and mes-
enchymal features with teratoid features, 2 cases were
fetal types, and 2 cases were hepatoblastomas (not
otherwise specified). Using PRETEXT staging [13], 4
cases were stage II, 5 cases were stage III, and 3 cases
were stage IV. Ten of twelve cases were undergoing
chemotherapy based on the JPLT-2 protocol, but only
two cases (HB05 and HB11) regressed to a lower stage
after chemotherapy.
Analyses of aberrant methylation and genetic alterations
at imprinted DMRs
We selected 33 regions reported previously as imprinted
DMRs in the human genome [11,14] (refer to http://
www.geneimprint.com/). Our strategy in this study
involved screening the methylation levels of DMRs in
tumors, their paired adjacent normal tissues, and normal
control livers by MALDI-TOF MS. The samples that
showed aberrant methylation were analyzed again by
pyrosequencing to confirm the result. These two methods
are the most reliable methods of methylation analysis at
present [10,15,16]. First, we analyzed the methylation level
of these regions in two normal livers, i.e. CL7 and CBD1,
by MALDI-TOF MS (Additional file 2: Figure S1). A total
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8 DMRs (IGF2R-DMR2, IGF2-DMR0, IGF2-DMR2, IG-
DMR-CG4, IG-DMR-CG6, TCEB3C-DMR, USP29-DMR,
and NNAT-DMR) showed mostly full methylation, and
5 DMRs (TP73-DMR, SPTBN1-DMR, WT1-AS-DMR,
DLK1-DMR, and GNASXL-DMR) showed mostly no
methylation. It is highly possible that these regions
were not differentially methylated in the normal liver,
probably due to tissue-specific and/or age-related features
of differential methylation, because most of the regions
were also analyzed by pyrosequencing and their methyla-
tion statuses were confirmed (Additional file 2: Figure S1).
Next, we screened the methylation status of the 33
DMRs in 12 hepatoblastomas and their paired adjacent
normal liver tissue by MALDI-TOF MS. We found
aberrant methylation in tumors and also in adjacent
liver tissue by comparing the methylation between
tumors and normal controls (TxC), tumors and adjacent
liver tissue (TxA), and adjacent liver tissue and normal
controls (AxC). The definition of aberrant methylation is
described in the Methods section. After excluding samples
harboring chromosomal abnormalities as described later,
we confirmed the aberrant methylation using pyrose-
quencing, except in the case of H19-DMR (representative
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Figure 1 Representative results of methylation analyses by MALDI-TO
aberrant hypomethylation. KvDMR1 of HB08 and PEG10 of HB11 are shown
tumor tissues, whereas PEG10-DMR was hypomethylated only in tumor tiss
INPP5Fv2-DMR in HB05 and RB1-DMR in HB11 are shown. Only tumors show
was defined as when more than 60% of total CpG units or CpG sites were
was defined as occurring when the difference of its methylation indexes in
methylation index; the horizontal axis represents CpG units (MALDI-TOF MS
normal control livers; blue line: adjacent normal liver; red line: tumor (hepaFigure S2). Additional normal control liver, CL16, was
used in pyrosequencing analyses. The methylation status
of H19-DMR was analyzed by hot-stop combined bisulfite
restriction analysis (COBRA) [17] or bisulfite sequencing
because of the difficulty in the primer-design for pyrose-
quencing (Additional file 4: Figure S3).
In order to exclude aberrantly methylated DMRs, as
associated with chromosome abnormalities, such as UPD
or copy number abnormality, DNA polymorphism analyses
using microsatellites and SNPs were performed on all
regions showing aberrant methylation in the MALDI-TOF
MS analyses. We found seven genetic alterations in four
tumors resulting in aberrant methylation: abnormal allelic
copy number of 11p13-p15.5 in HB01, 20q11-q13 in
HB05, and 19q13 and 20q13 in HB11; LOH of 7q32.2
and 11p15.5 in HB11; and paternal UPD of 11p13-
p15.5 in BWS109 (Figure 2). We speculated the allelic
imbalance statuses of these loci according to the results
of MALDI-TOF MS analysis and DNA polymorphism
analysis (Additional file 5: Figure S4). HB01 would harbor
more paternal copies than the maternal copies in 11p13-
p15.5. An abnormal allelic copy number of 20q11-q13
in HB05 would represent a higher copy number in the
maternal allele than the paternal allele. HB11 would







































































P1 P2 P3 P4 P5 P6 P7 P8
F MS and pyrosequencing. (A and B) Representative samples of
. KvDMR1 was hypomethylated in both adjacent normal liver and
ue. (C and D) Representative samples of aberrant hypermethylation.
ed hypermethylation at these DMRs. Aberrant methylation of a DMR
aberrantly methylated. Aberrant methylation of a CpG unit or CpG site
two samples exceeded 0.15. The vertical axis represents the
) or CpG sites (pyrosequencing) analyzed. Green line: average of
toblastoma).





























































































Pat/mat Mat Mat Unknown Unknown Pat Mat Mat Unknown Mat Mat Mat Pat Pat Pat Pat Mat Unknown
Gametic/
Somatic
Gametic Gametic Unknown Unknown Somatic Gametic Gametic Unknown Gametic Gametic Gametic Somatic Gametic Somatic Somatic Gametic Unknown
Category AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA AxC TxC TxA
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HB11 ACN ACN ACN ACN ACN ACN
BWS109
Figure 2 Aberrant methylations and genetic alterations of 33 imprinted DMRs in 12 hepatoblastomas. Aberrant hypomethylation and
aberrant hypermethylation found in each comparison are indicated by blue and red boxes, respectively. Aberrant methylation was identified by
comparing adjacent normal liver tissue with normal control livers: AxC; tumors compared with normal control livers: TxC; and tumors compared
with adjacent normal livers: TxA. The classes of these DMRs in previous reports are shown in Pat/Mat and Gametic/Somatic rows. ZDBF2-DMR was
tentatively assigned as a somatic DMR based on experiments from mice [35]. MALDI-TOF MS revealed that 13 DMRs, such as TP73-DMR, SPTBN1-DMR,
IGF2R-DMR2, IGF2-DMR0, IGF2-DMR2, WT1-AS-DMR, DLK1-DMR, IG-DMR-CG4, IG-DMR-CG6, TCEB3C-DMR, USP29-DMR, NNAT-DMR, and GNASXL-DMR did
not show differential methylation in control livers. Most of these methylation statuses were confirmed by pyrosequencing analysis. Mat: maternally
methylated DMR; Pat: paternally methylated DMR; gametic: gametic DMR; somatic: somatic DMR. ACN: abnormal copy number; LOH: loss of
heterozygosity; UPD: paternal uniparental disomy; DD: difficult to decide.
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occurred due to a paternal deletion and a maternal dele-
tion, respectively. The paternal UPD was confirmed using
the parents’ DNA (Additional file 5: Figure S4). The extent
of the UPD was found to be at 11p11.2–pter by a SNP
array analysis (data not shown).
The following results described are shown in Figure 2.
All tumors carried aberrant methylation in at least one
DMR. HB05 carried aberrant methylations at 8 DMRs,
the highest number of aberrant methylations, whereas
HB03 and HB08 carried aberrant methylations at only
one DMR, MCTS2-DMR and KvDMR1, respectively. A
total of 18 of 33 DMRs showed aberrant methylation,
whereas 15 DMRs did not show such features in any
tumors. There was large deviation in the incidence of
aberrant methylation among the DMRs. KvDMR1 and
IGF2-DMR0 were the most frequently hypomethylatedDMRs in 3 of 9 tumors. The most frequently hypermethy-
lated DMR was INPP5Fv2-DMR, which occurred in 7
of 12 samples. RB1-DMR was also hypermethylated
with a high frequency, which occurred in 5 of 12 samples.
In addition, GNASXL-DMR was hypermethylated in 4
of 10 samples. The following DMRs showed aberrant
methylation in only one tumor: ARH1-CG1, NAP1L5-
DMR, PEG10-DMR, H19 promoter,WT1-AS-DMR,MEG3-
CG7-DMR, MCTS2-DMR, NESP-DMR, and GNAS1A-
DMR.
Two chromosomal loci, 11p15.5 and 20q13.32, showed
high frequencies of genetic and epigenetic alterations at
10 of 12 and 7 of 12, respectively. In the 11p15.5 locus,
seven tumors carried the aberrant methylation and three
samples carried genetic alterations. In the 20q13.32
locus, five tumors carried aberrant methylation and two
carried an abnormal allelic copy number.
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We compared the numbers of aberrantly hypomethylated
and hypermethylated DMRs in three pairs of the sample
groups (Figure 3A). We excluded the DMRs harboring
UPD or copy number abnormalities for the statistical
analyses. Comparing adjacent normal liver tissues (A) and
control livers (C), herein denoted as AxC, only hypome-
thylation was observed in adjacent normal liver tissue
(p = 0.031). In the TxC comparison, both hypermethylation
and hypomethylation were observed in tumors (no signifi-
cant difference). In the TxA comparison, hypermethylation
was observed more frequently than hypomethylation with
statistical significance (p = 0.013). In addition, the number
of hypomethylated DMRs in tumors was higher than

















































































Figure 3 Comparison of aberrant methylations of DMRs in hepatobla
(blue bars) and hypermethylated (red bars) DMRs. Hypomethylation, but no
Hypermethylation was observed more frequently than hypomethylation in
frequencies of aberrant methylations between the paternally methylated D
Left and right panels indicate hypomethylation and hypermethylation, respec
hypermethylation. (C) Comparison of the frequencies of aberrant methylation
Left and right panels indicate hypomethylation and hypermethylation, respec
with statistically significant difference in tumors compared to control livers. Th
the total numbers of DMRs in the two categories compared; that is, the pater
asterisks indicated significant difference. The p values are shown above the coBonferroni correction did not show statistical significance
of the difference with a significance level of 0.05/3 (ap-
proximately 0.0167). These results suggested a possibility
that hypomethylation occurred at certain DMRs in
adjacent normal liver tissue prior to tumor development,
whereas hypermethylation occurred only within the tumor
tissue itself.
We further compared the frequencies of aberrant methy-
lation between paternally methylated DMRs and maternally
methylated DMRs. As for hypomethylation, there was no
significant difference between the two kinds of DMRs in
each comparison (Figure 3B, left panel). In contrast, hyper-
methylation, which was observed only in tumors, tended to
occur more frequently at maternally methylated DMRs




























































stoma. (A) Comparison of the numbers of aberrantly hypomethylated
t hypermethlation, was observed in adjacent normal tissues.
tumors compared to adjacent normal tissues. (B) Comparison of the
MRs (black bars) and the maternally methylated DMRs (white bars).
tively. There was no significant difference in both hypomethylation and
s between gametic DMRs (yellow bars) and somatic DMRs (green bars).
tively. Hypermethylation was observed more frequently at gametic DMRs
e frequencies were compared in (B) and (C) because of the difference in
nal and the maternal DMRs or the gametic and the somatic DMRs. The
mparisons. b: binomial test, c: chi squared test.
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the frequencies of aberrant methylation between gametic
DMRs and somatic DMRs. No significant difference in
hypomethylation was found between the two kinds of
DMRs in each comparison (Figure 3C, left panel). In
contrast to hypomethylation, hypermethylation occurred at
gametic DMRs more frequently with statistical significance
(p = 0.043) (Figure 3C, right panel). This difference was
mainly due to the frequent occurrence of hypermethylation
at three maternally methylated and gametic DMRs,
such as INPP5Fv2-DMR, RB1-DMR, and GNASXL-DMR
(Figure 2).
Methylation status of LINE-1 in hepatoblastoma
We analyzed the methylation status of LINE-1 in all
samples by pyrosequencing to assess the genome-wide
methylation level. LINE-1 is a human repetitive element
and constitutes approximately 30% of the human genome
[18]. Its methylation status has been used as a surrogate
marker for genome-wide DNA hypomethylation in many
cancers [19,20]. We analyzed the methylation of four CpG
sites in a LINE-1 sequence that were hypomethylated in
cancers [21,22]. We compared the methylation levels of
each CpG site among the three groups using Bonferroni
correction with significance level of 0.0167 (Figure 4).
Tumors showed slight hypomethylation only at CpG1
among four CpGs (p = 0.015 in TxA). However, other
CpG sites did not show hypomethylation although bare
hypermethylations (less than 2.5%) was found only in
adjacent normal liver tissues at CpG2 (p = 0.001 in AxC
and p = 0.010 in AxT). These results suggested that theFigure 4 Methylation status of LINE-1. Methylation levels of four succes
adjacent normal liver tissues (A), and three normal control livers (C) by pyro
average values were plotted with standard deviations. The average values
indicated significant differences (p < 0.0167). Bonfferoni correction was appgenome-wide methylation levels were almost same among
three sample groups.
Discussion
In this study, we found many imprinted DMRs methylated
aberrantly in hepatoblastomas and paired adjacent normal
liver tissue. An important finding was that the aberrant
hypomethylation occurred not only in tumor tissue but also
in adjacent normal liver tissue. One possible explanation
is that the occurrence of the aberrant hypomethylation at
certain DMRs may be a very early and specific event prior
to tumor development, although there is another possibility
that the tumor may induce methylation changes in the
adjacent tissues. Okamoto et al. have previously reported a
similar phenomenon with respect to aberrant hyperme-
thylation of H19-DMR that was frequently found in
normal tissues adjacent to Wilms’ tumors, which carried
the same aberrant methylation [23]. Based on the results,
it was hypothesized that the preceding aberrant methyla-
tion may be a constitutional aberration in the onset of
embryonal tumors. In contrast to the hypomethylation,
the aberrant hypermethylation of the DMR occurred only
in tumors. These results indicated that the hypermethyla-
tion of the DMRs, especially for INPP5Fv2-DMR, RB1-
DMR, and GNASXL-DMR, was a specific event for tumor
development; this suggested that the pre-cancerous cells
did not carry hypermethylation at the DMRs, but acquired
the aberrant methylation during tumor development.
We also analyzed the genome-wide methylation level,
represented by LINE-1 methylation, and we did not
find large difference among three sample groups as asive CpG sites in LINE-1 were analyzed in hepatoblastomas (T), paired
sequencing. The normal controls were analyzed in triplicate and the
of methylation (%) are shown for each sample groups. The asterisks
lied for this statistical analysis.
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tumors, and its methylation level correlates with clinico-
pathological features of the tumors [19]. The different
situation concerning LINE-1 methylation between hepato-
blastoma and adult tumors may reflect a different mech-
anism of tumorigenesis in embryonal tumors as compared
to adult tumors.
Hypermethylation in tumors was frequently observed at
three DMRs, INPPF5v2-DMR, RB1-DMR, and GNASXL-
DMR. INPPF5v2-DMR controls the expression of INPP5F
transcript variant 2, which encodes a protein of an
unknown function [24,25]. RB1-DMR, located in intron 2
of the RB1 gene, leads to maternal expression of transcript
variants from exon 2B with very low expression in
normal tissues [26]. The function of the variants in cell
proliferation is not known. Thus, the effect of these
hypermethylated DMRs on tumorigenesis would be
little or unknown. GNASXL-DMR is associated with
the paternal expression of GNASXL, which encodes a
protein involved in signal transduction [27-29]. The DMR
was shown to be mostly unmethylated in control livers
(Additional file 2: Figure S1). Thus, hypermethylation of
GNASXL-DMR would reduce expression of GNASXL.
Unfortunately, the expression of genes linked to aberrantly
methylated DMRs could not be analyzed due to poor RNA
quality, which was probably due to effects of chemotherapy
and a limited amount of samples. Therefore, we could
not assess the involvement of hypermethylation in tumori-
genesis of hepatoblastoma.
Another important finding was the frequent occurrence
of both genetic and epigenetic alterations at the two
chromosomal loci, 11p15.5 and 20q13.3. The 11p15.5 locus
is a well-known imprinted locus responsible for BWS, a
tumor-predisposing imprinting disorder. The locus was
found to be altered genetically and/or epigenetically in
10 of 12 tumors. Hypermethylation at H19-DMR and
hypomethylation at IGF2-DMR0 associated with biallelic
expression of IGF2 were reported in adult and embryo-
logical tumors, including hepatoblastoma [6,7]. Hyper-
methylation at H19-DMR and the H19 promoter also
reduced the expression of H19 in Wilms’ tumor [30,31].
In addition to epigenetic alterations, genetic alterations,
such as the amplification of paternal alleles leading to
overexpression of IGF2 and LOH of the maternal allele
leading to reduced expression of H19, were observed in
sporadic Wilms’ tumors [32,33]. In this study, in addition
to the hypermethylations at H19-DMR and the H19
promoter in two tumors, hypomethylation at IGF2-
DMR0 occurred in another two adjacent normal liver
tissues. Further, abnormal allelic copy number, paternal
UPD, and maternal LOH of 11p15.5 were observed.
The overexpression of IGF2 and the reduced expression
of H19 would play an important role in tumorigenesis
of hepatoblastoma.The 20q13.3 locus was also altered genetically and/or
epigenetically in 7 of 12 tumors. This locus is responsible
for pseudohypoparathyroidism, a condition in which patho-
genesis is attributed to the tissue specific imprinting of Gsα,
for example, which occurs in the proximal renal tubule. On
the other hand, an extra copy of chromosome 20 has been
known to be the most recurrent cytogenetic alteration in
hepatoblastoma [2,34]. We found copy number differences
of the alleles in this region, suggesting the existence of
non-imprinted oncogenic gene(s) in this region.
Many epigenetic and genetic alterations were found at
the loci linked to the 33 imprinted DMRs in 12 hepato-
blastomas. However, since sample numbers in this study
were small, more hepatoblastoma samples should be
analyzed to confirm the present data and to evaluate
the precise role of these alterations in tumorigenesis in
addition to assessing their usefulness as markers for
clinical characteristics, such as stage classification, response
to chemotherapy, and prognosis. Also needed are the
expression analyses of the genes linked to aberrantly
methylated DMRs to assess their role in tumor develop-
ment, although it is very difficult to obtain hepatoblastoma
samples without any chemotherapeutic history.
Conclusions
We found epigenetic and genetic characteristics of
hepatoblastoma by comprehensive epigenetic and gen-
etic analyses of 33 DMRs linked to imprinting loci in
12 hepatoblastoma samples and their adjacent normal
liver tissues. These included aberrant hypomethylation in
adjacent normal liver tissue, tumor-specific hypermethyla-
tion, and the frequent occurrence of both genetic and
epigenetic alterations at 11p15.5 and 20q13.3 loci. Further
studies using more hepatoblastoma samples are needed to
confirm the present results and evaluate their roles in the
tumor development.
Additional files
Additional file 1: Table S1. Primers used for this study.
Additional file 2: Figure S1. Maps of DMRs analyzed in this study and
their methylation status in normal control livers. Upper part; The arrow
represents the position and the direction of the transcription start site
(TSS). P: promoter; Cen: centromere; Tel: telomere; yellow box (CGI): CpG
island; orange boxes (M): CpG sites analyzed by MALDI-TOF MS; green
boxes (P): CpG sites analyzed by pyrosequencing. Numbers with diagonal
lines indicate CpG units (MALDI-TOF MS) or CpG sites (pyrosequencing),
which could not be analyzed. Figures are not drawn to scale. Lower part;
Results of MALDI-TOF MS and pyrosequencing are shown. In methylation
graphs, the vertical axis represents the methylation index (0: no methyla-
tion; 1: full methylation). The horizontal axis represents CpG units or CpG
sites. CL7 was analyzed in duplicate by MALDI-TOF MS analysis. Blue and
red lines: CL7; green line: CBD1; dark grey line: CL16.
Additional file 3: Figure S2. Methylation data of the aberrantly
methylated DMRs in hepatoblastomas. The results of MALDI-TOF MS
(left panel) and pyrosequencing (right panel) are shown. The vertical axis
represents the methylation index (0–1); the horizontal axis represents
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http://www.biomedcentral.com/1471-2407/13/608CpG units (MALDI-TOF MS) or CpG sites (pyrosequencing). Green line:
average of control livers; blue line: adjacent normal liver; red line:
tumor (hepatoblastoma).
Additional file 4: Figure S3. Methylation status of H19-DMR as
determined by bisulphite cloning sequencing and hot-stop COBRA. (A)
Bisulphite sequencing of HB05, which was heterozygous for rs2071094.
Filled circle: methylated CpG site; open circle: unmethylated CpG site.
rs2071094: single nucleotide polymorphisms (A/T). CTCF6: CTCF binding
site 6. TaqI: TaqI site used for hot-stop COBRA. (B) Hot-stop COBRA. End-
labeled PCR products were obtained by PCR with 32P labeled reverse primer
in the final amplification cycle. The PCR products were digested with TaqI
overnight and then electrophoresed. Band intensities were quantitated
using the FLA-7000 fluoro-image analyzer (Fujifilm, Japan). un: unmethylated
control DNA; me: fully methylated control DNA.
Additional file 5: Figure S4. Genetic alterations in hepatoblastoma. (A)
Map of 11p15-p13 is shown uppermost. Black box: microsatellite marker;
white box: DMR analyzed. Tel: telomere; Cen: centromere. Figure is not drawn
to scale. Below the map, the representative data of the methylation analyses
and microsatellite analyses are shown for three hepatoblastomas. For HB01
tumor, a high paternal copy number was estimated because of the hyperme-
thylation at the paternally methylated H19-DMR and the hypomethylation at
the maternally methylated KvDMR1. LOH in HB11 tumor was indicated by the
near loss of one of two alleles. The maternal allele could have been lost
because of hypermethylation at H19-DMR and hypomethylation at KvDMR1.
The deviation of the allelic ratio in adjacent normal liver and tumor tissue
indicates paternal UPD mosaicism in BWS109, whereas the allelic ratios in the
parental blood were approximately 1. The level of mosaicism was higher in
tumor than in adjacent normal liver tissue. In tumor samples, the value of the
higher peak was divided by that of the lower peak. In adjacent normal liver
and parental samples, the ratios were calculated following the pattern in their
related tumor. (B) LOH of 7q32 in HB11 tumor was indicated. Because of the
hypermethylation at the maternally methylated MEST-DMR, the paternal allele
would have been lost. (C) Higher maternal copy number of 19q13 were
suggested in HB11 tumor, based on the allelic ratio of D19S589 and the
hypermethylation at the maternally methylated PEG3-DMR. (D) Allelic copies of
20q11-q13 in HB05 and HB11 tumors were suggested to be abnormal by the
allelic ratios of D20S438 and D20S158. Based on the abnormal methylations at
the paternally methylated NESP-DMR, HB05 tumor would carry more maternal
copies than paternal copies of the locus, whereas in HB11 tumor, the paternal
allelic copy number would be higher. (PDF 584 kb)
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